Roche Holding AG (OTCMKTS:RHHBY) Given Average Recommendation of “Hold” by Brokerages

Roche Holding AG (OTCMKTS:RHHBY) has received a consensus rating of “Hold” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $60.00.

RHHBY has been the topic of several recent analyst reports. Morgan Stanley raised Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price target on the stock in a research report on Friday, August 7th. Zacks Research downgraded Roche from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Finally, HSBC cut shares of Roche from a “buy” rating to a “hold” rating in a research note on Monday, July 6th.

Roche Price Performance

Shares of OTCMKTS RHHBY opened at $58.10 on Monday. The stock has a 50 day moving average price of $53.30 and a 200 day moving average price of $52.93. Roche has a 52 week low of $39.50 and a 52 week high of $60.85. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. McIlrath & Eck LLC acquired a new position in shares of Roche during the 1st quarter worth about $39,000. Oakworth Capital Inc. lifted its stake in Roche by 20.8% in the 4th quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock valued at $86,000 after purchasing an additional 285 shares during the last quarter. Atlas Capital Advisors Inc. bought a new position in Roche during the fourth quarter worth about $192,000. Pinnacle Wealth Management Advisory Group LLC bought a new position in Roche during the first quarter worth about $208,000. Finally, Renasant Bank acquired a new position in Roche during the second quarter worth approximately $210,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.